Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Antabuse
Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Disulfiram (brand Antabuse; generics) is an aversive-therapy medication for alcohol use disorder (AUD). It inhibits aldehyde dehydrogenase so alcohol exposure can trigger an acetaldehyde reaction (label).
Because the clinical effect depends on consistent adherence, outcomes are best when dosing is supervised or strongly supported and when the goal is abstinence (guideline/clinical).
Disulfiram is not a withdrawal treatment; alcohol withdrawal is managed separately, then relapse-prevention options are considered during ongoing recovery care (guideline/clinical).
Key safety issues include severe reactions with alcohol exposure, hepatotoxicity risk, and medication interactions (label/clinical).
The compare view, disulfiram evidence feed, and disulfiram print page support counseling when abstinence-focused options are being weighed against side effects and practical constraints.
Often reserved for selected patients when abstinence is the goal and when supervised dosing is feasible. Hidden alcohol exposure and hepatotoxicity monitoring are common barriers to use.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation after alcohol ingestion and an aversive physiologic reaction (label).
The aversive mechanism relies on consistent dosing and consistent alcohol avoidance; it does not directly treat cravings in the way some other options may (review/guideline).
Many programs document informed consent about reaction severity and avoidance of alcohol for up to 14 days after discontinuation (label).